Shots: Audentes and NCH enter into a license agreement to develop AT702 designed to induce exon 2 skipping in DMD patients with exon 2 duplications and mutations in exons 1-5 […]readmore
Tags : Audentes
Shots: The update in the development is based on ASPIRO P-I/II study results assessing AT132 in 12 patients aged≤ 5 yrs. following a pre-IND meeting of AT132 with FDA in […]readmore